DDIs with new DAAs Franco Maggiolo AO Papa Giovanni XXIII Bergamo.

Slides:

Advertisements

Similar presentations

Cytochrome enzymes metabolism Genetic variation in processes involved in the absorption, distribution, metabolism, or elimination of a drug can result.

Advertisements

Module II The Basics of the Brain, the Body and Drug Actions

TB & HIV Infection: Treatment

TB & HIV Infection: Treatment Your name Institution/organization Meeting Date International Standard 8, 13 TB & HIV Infection: Treatment Your name Institution/organization.

Long Term effects of drugs on the brain

Daniel Everitt, MD; Erica Egizi MPH Global Alliance for TB Drug Development, New York Helen Winter, PhD University of Otago, New Zealand 2012 International.

VIREAD (Tenofovir DF) Update. Viread Update  Pharmacokinetics  Safety & Tolerability  Efficacy  Virology.

Flucoral® Pharmacological Composition Each capsule containing 150mg Fluconazole. Fluconazole is a broad spectrum Systemic Antifungal.

DISTRIBUTION The body is a container in which a drug is distributed by blood (different flow to different organs) - but the body is not homogeneous. Factors.

Pharmacotherapy in the Elderly Judy Wong

HIV and Psychiatric Medication Interactions

Absorption, Distribution, Metabolism and Elimination: Part II

Chapter 6 Drug Interactions 1.

Background: Focus on P-gp Questions:

New Agents Heather Kertland, PharmD.

Pharmacokinetics: Bioavailability Asmah Nasser, M.D.

1 Pharmacokinetics and Drug Interactions HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Basic & Clinical Pharmacology Influence of liver impairment in the action of sodium thiopental.

Mechanisms of Toxicity

Progress in utilization of Mycobacterium tuberculosis cytochrome P450 monooxygenases as novel drug targets Central University of Technology Bloemfontein,

Pharmacokinetics of Saquinavir hard gel (Invirase) when combined with Atazanavir 8.11 D Prelutsky 1, P Salvato 2, R Falcon 3 1. Washington University School.

Psychobiology Research Group Pharmacokinetics and Phamacogenetics Hamish McAllister-Williams PhD, MD, FRCPsych Reader in Clinical Psychopharmacology Newcastle.

Non-linear Pharmacokinetics Arthur G. Roberts. Linear Pharmacokinetics AUC dose K Cl dose [Drug] plasma time ln[Drug] plasma time Increasing Dose.

Lecture 2.  Clearance Ability to eliminate the drug  Volume of distribution (Vd) The measure of the apparent space in the body available to contain.

Pharmacogenetics & Pharmacogenomics Personalized Medicine.

PLASMA HALF LIFE ( t 1/2 ).  Minimum Effective Concentration (MEC): The plasma drug concentration below which a patient’s response is too small for clinical.

1 Pharmacology Pharmacokinetics –Absorption –Distribution –Biotransformation (metabolism) –Excretion Pharmacodynamics –Receptor binding –Signal transduction.

GS-9350: A Pharmacoenhancer Without anti-HIV Activity AA Mathias, P German, M Lee, C Callebaut, L Xu, L Tsai, B Murray, H Liu, K Yale, D Warren and BP.

PO 2726; IAS; Vicriviroc (formerly SCH ): Antiviral Activity of a Potent New CCR5 Receptor Antagonist D. Schuermann, C. Pechardscheck, R. Rouzier,

May 19, 2005FDA Antiviral Drugs Advisory Committee Meeting 1 Tipranavir NDA Drug Interactions Yuanchao (Derek) Zhang, Ph.D. Clinical Pharmacology.

© 2008 Universitair Ziekenhuis Gent PHARMACOKINETICS IN CKD R Vanholder University Hospital, Gent, Belgium.

Principles of pharmacokinetics Prof. Kršiak Department of Pharmacology, Third Faculty of Medicine, Charles University in Prague Cycle II, Subject: General.

Overview of Drug Interactions Between Brecanavir (BCV) and Other HIV Protease Inhibitors (PIs) M Shelton, S Ford, M Anderson, S Murray, J Ng-Cashin XVI.

© Paradigm Publishing, Inc.1 Chapter 2 Basic Concepts of Pharmacology.

DRUG INTERACTIONS I Lecture #36. Drug Interactions Terms Therapeutic Drug Interaction ADR Additive Synergism.

Antiretrovirals III: Pharmacokinetics and Drug Interactions

Pharmacokinetics 2 General Pharmacology M212

Emmanuelle Germain, Joelle Chevalier, Marlène Steib, Marie-Hélène Siess* and Caroline Teyssier* Institut National de la Recherche Agronomique / ENSBANA,

METABOLISME DEPARTMENT OF PHARMACOLOGY AND THERAPEUTIC UNIVERSITAS SUMATERA UTARA dr. Yunita Sari Pane.

Basic Concepts of Pharmacology © Paradigm Publishing, Inc.

Cytochrome P 450 Biochemistry Department. Cytochrome P 450 Unique family of heme proteins present in bacteria, fungi, insects, plants, fish, mammals and.

Drug X S-warfarin Agents that DECREASE metabolism (inhibit or compete for cytochrome P450) are more important than those that increase metabolism.

Genotype-directed dosing for Efavirenz

Optimizing Antiretorviral Therapy for Long-Term HIV Care

Enzymes Definition and Classification

TDF-FTC vs. ABC-3TC, each with Atazanavir + RTV or Efavirenz ACTG 5224s (Bone Effects): Study Design

Pharmacokinetics.

Enzymes and drugs P450 enzymes breakdown/metabolize active drug

Bioavailability of a drug from an immediate-release tablet containing 50 mg of drug given at 0, 4, and 8 hours compared to a single 150-mg drug dose given.

Drug Metabolism Drugs are most often eliminated by biotransformation and/or excretion into the urine or bile. The process of metabolism transforms lipophilic.

BIOTRANSFORMATION, Drug metabolism, detoxification

Drug Elimination Drug elimination consists of 2 processes

Drugs, drugs, and more drugs…

Understanding the Basics of Pharmacology

Anti-fungal agents Problem: Fungi are eukaryotes

Pharmacokinetics and Drug Interactions in the new HCV Clinical Management SOC.

PCP View: ACC/AHA Guidelines: Role of Moderate Intensity Statins

Conceptual Subdivisions of Pharmacology

Next Generation Capsid Inhibitor: GS–CA1

Conceptual Subdivisions of Pharmacology

Selected Bioavailability and Pharmacokinetic Calculations

How to Add temperature & plug/monitor info?

Volume 68, Issue 4, Pages (April 2018)

Project #1: Drug Kinetics in Genetically Modified Mice

Aaron T. Wright, Benjamin F. Cravatt Chemistry & Biology

Pharmacology The science of Drugs.

Drug clearance by metabolism can also decrease with declining kidney function. Drug clearance by metabolism can also decrease with declining kidney function.

Presentation transcript:

DDIs with new DAAs Franco Maggiolo AO Papa Giovanni XXIII Bergamo

3 CYP450 The P450 cytochromes chemically oxidize or reduce drugs > than 25 human cytochrome P450’s They are named by number and letter: 4 major families  indicated by number 6 major sub-families  indicated by letter Individual enzymes within a subfamily  indicated by number For example 3A4, 2D6, 2C19 Badea G. Drug Metabolism. Feb 2007

CYP 3A4 activity 300% 200% 100% 0% EFV introductionwithdrawal [c] CYP 3A4 activity 300% 200% 100% 0% RTV introductionwithdrawal [c] 6-10 hours 2-3 weeks

Drug transporters

7 P-glycoprotein Transports drugs out of the cell Tissue expression is varied Found in the major absorption, distribution and elimination organs P-gp inducers and inhibitors\ Source:

Paritaprevir kinetics

C min < 59% (dose 90 mg) C min > 265% (dose 30 mg) C min > 163% C max > 79% DAAs’ DDIs

C min < 48% C min > 4,58 fold C min < 91% expected to decrease C min Exposure 3 fold increase (QT prolungation risk) DAAs’ DDIs

DAAs’ DDIs management Choice of DAA combination (protease inhibitors?) Modify cART (NRTI, INI, RPV, [ATV, EFV]) Closely monitor Rx tolerability Modify (eventually) associated Rx Temporarly sospend associated Rx